Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205294 | 0.92 | F10 (0.31) | L3MBTL1 | |
| SCHEMBL7200171 | 0.92 | CNR2 (0.32) | MCHR1 | |
| SCHEMBL7198867 | 0.91 | ABHD16A (0.34) | — | |
| SCHEMBL7201125 | 0.90 | — | — | |
| SCHEMBL7202223 | 0.90 | — | — | |
| SCHEMBL7203900 | 0.90 | RXFP1 (0.33) | — | |
| SCHEMBL7198871 | 0.89 | TSHR (0.33) | — | |
| SCHEMBL7201093 | 0.89 | DPP4 (0.30) | DPP4 | |
| SCHEMBL7202837 | 0.89 | — | — | |
| SCHEMBL7199833 | 0.87 | KDM1A (0.33) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | claimed |
| EP-1234834-A1 | 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | claimed |
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1234834-A1 | 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | SERPINB1, ELANE, MMP8 | LGMN 458/4885TRPV1 2607/4885DPP4 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.